BioXcel Therapeutics (BTAI) Operating Income (2022 - 2025)
Historic Operating Income for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$14.2 million.
- BioXcel Therapeutics' Operating Income rose 696.4% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.7 million, marking a year-over-year increase of 3387.19%. This contributed to the annual value of -$67.2 million for FY2024, which is 6085.45% up from last year.
- Latest data reveals that BioXcel Therapeutics reported Operating Income of -$14.2 million as of Q3 2025, which was up 696.4% from -$15.9 million recorded in Q2 2025.
- BioXcel Therapeutics' Operating Income's 5-year high stood at -$10.1 million during Q1 2025, with a 5-year trough of -$52.9 million in Q4 2022.
- In the last 4 years, BioXcel Therapeutics' Operating Income had a median value of -$24.2 million in 2024 and averaged -$29.3 million.
- Per our database at Business Quant, BioXcel Therapeutics' Operating Income tumbled by 6263.66% in 2023 and then soared by 6833.55% in 2024.
- Over the past 4 years, BioXcel Therapeutics' Operating Income (Quarter) stood at -$52.9 million in 2022, then surged by 62.42% to -$19.9 million in 2023, then surged by 47.21% to -$10.5 million in 2024, then tumbled by 35.6% to -$14.2 million in 2025.
- Its Operating Income stands at -$14.2 million for Q3 2025, versus -$15.9 million for Q2 2025 and -$10.1 million for Q1 2025.